-
Something wrong with this record ?
Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab
O. Lidický, P. Klener, D. Machová, P. Vočková, E. Pokorná, K. Helman, C. Mavis, O. Janoušková, T. Etrych
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NV17-28980A
MZ0
CEP Register
- MeSH
- Pharmaceutical Preparations * MeSH
- Humans MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Lymphoma, Non-Hodgkin * drug therapy MeSH
- Polymers therapeutic use MeSH
- Antineoplastic Agents * therapeutic use MeSH
- Rituximab MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
B-cell non-Hodgkin lymphomas (B-NHL) represent the most common type of hematologic malignancies in the Western hemisphere. The therapy of all B-NHL is based on the combination of different genotoxic cytostatics and anti-CD20 monoclonal antibody (mAb) rituximab. Unfortunately, many patients relapse after the mentioned front-line treatment approaches. The therapy of patients with relapsed/refractory (R/R) B-NHL represents an unmet medical need. We designed, developed and tested novel actively targeted hybrid mAb-polymer-drug conjugate (APDC) containing anti-CD20, anti-CD38 or anti-CD19 mAbs. Biocompatible copolymers based on N-(2-hydroxypropyl)methacrylamide (HPMA) with cytostatic agent doxorubicin attached via stimuli-sensitive hydrazone bond were employed for the mAb grafting. Anti-lymphoma efficacy of the APDC nanotherapeutics was evaluated in vivo on a panel of three patient-derived lymphoma xenografts derived from two patients with R/R B-NHL and one patient with so far untreated B-NHL. In both PDX models derived from patients with R/R B-NHL, the targeting with anti-CD38 antibody daratumumab demonstrated highly improved anti-lymphoma efficacy compared to the targeting with anti-CD20 rituximab, two experimental anti-CD19 antibodies and non-targeted controls. The results represent a proof-of-concept of a new algorithm of personalized anti-tumor therapy based on highly innovative APDC biomaterials.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019665
- 003
- CZ-PrNML
- 005
- 20210830101244.0
- 007
- ta
- 008
- 210728s2020 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jconrel.2020.08.042 $2 doi
- 035 __
- $a (PubMed)32860930
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Lidický, Ondřej $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic
- 245 10
- $a Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab / $c O. Lidický, P. Klener, D. Machová, P. Vočková, E. Pokorná, K. Helman, C. Mavis, O. Janoušková, T. Etrych
- 520 9_
- $a B-cell non-Hodgkin lymphomas (B-NHL) represent the most common type of hematologic malignancies in the Western hemisphere. The therapy of all B-NHL is based on the combination of different genotoxic cytostatics and anti-CD20 monoclonal antibody (mAb) rituximab. Unfortunately, many patients relapse after the mentioned front-line treatment approaches. The therapy of patients with relapsed/refractory (R/R) B-NHL represents an unmet medical need. We designed, developed and tested novel actively targeted hybrid mAb-polymer-drug conjugate (APDC) containing anti-CD20, anti-CD38 or anti-CD19 mAbs. Biocompatible copolymers based on N-(2-hydroxypropyl)methacrylamide (HPMA) with cytostatic agent doxorubicin attached via stimuli-sensitive hydrazone bond were employed for the mAb grafting. Anti-lymphoma efficacy of the APDC nanotherapeutics was evaluated in vivo on a panel of three patient-derived lymphoma xenografts derived from two patients with R/R B-NHL and one patient with so far untreated B-NHL. In both PDX models derived from patients with R/R B-NHL, the targeting with anti-CD38 antibody daratumumab demonstrated highly improved anti-lymphoma efficacy compared to the targeting with anti-CD20 rituximab, two experimental anti-CD19 antibodies and non-targeted controls. The results represent a proof-of-concept of a new algorithm of personalized anti-tumor therapy based on highly innovative APDC biomaterials.
- 650 _2
- $a monoklonální protilátky $x terapeutické užití $7 D000911
- 650 12
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nehodgkinský lymfom $x farmakoterapie $7 D008228
- 650 12
- $a léčivé přípravky $7 D004364
- 650 _2
- $a polymery $x terapeutické užití $7 D011108
- 650 _2
- $a rituximab $7 D000069283
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Klener, Pavel $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague 2, Czech Republic; First Department of Internal Medicine- Hematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08 Prague 2, Czech Republic
- 700 1_
- $a Machová, Daniela $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic
- 700 1_
- $a Vočková, Petra $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague 2, Czech Republic; First Department of Internal Medicine- Hematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08 Prague 2, Czech Republic
- 700 1_
- $a Pokorná, Eva $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague 2, Czech Republic
- 700 1_
- $a Helman, Karel $u Faculty of Informatics and Statistics, University of Economics, Prague, Czech Republic
- 700 1_
- $a Mavis, Cory $u Department of Medicine Lymphoma/Myeloma, Roswell Park, Comprehensive Cancer Center, Elm & Carlton Sts, Buffalo, NY 14263, United States of America
- 700 1_
- $a Janoušková, Olga $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic
- 700 1_
- $a Etrych, Tomáš $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic. Electronic address: etrych@imc.cas.cz
- 773 0_
- $w MED00002621 $t Journal of controlled release : official journal of the Controlled Release Society $x 1873-4995 $g Roč. 328, č. - (2020), s. 160-170
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32860930 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101244 $b ABA008
- 999 __
- $a ok $b bmc $g 1690474 $s 1140111
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 328 $c - $d 160-170 $e 20200827 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
- GRA __
- $a NV17-28980A $p MZ0
- LZP __
- $a Pubmed-20210728
